Back HIV/AIDS HIV/AIDS Topics HIV Prevention

IAS 2015: ADAPT Study Shows PrEP Feasibility [VIDEO]

Results from the HPTN 067 or ADAPT trial -- a study of Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis for gay men in New York City and Bangkok, and heterosexual women in Cape Town -- add to the growing body of evidence about how best to use PrEP and how its protective effect may vary across population groups and with different dosing schedules, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

Read more:

IAS 2015: Information about HIV Treatment as Prevention Lessens Stigma and Increases Testing

A large randomized trial of communities in rural Malawi shows that a single community meeting providing information on how antiretroviral therapy makes people less likely to transmit the virus can have a significant impact both on HIV stigma and HIV testing. The results were presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) last month in Vancouver.

alt

Read more:

IAS 2015: High Adherence and No HIV Infections Seen in Heterosexual PrEP Study in Botswana

A study of open-label Truvada HIV pre-exposure prophylaxis (PrEP) among heterosexual people in Botswana found very high adherence rates. Around 90% of participants had useful levels of the drug in their blood, there was a high concordance between self-reported adherence and drug levels, and there were no HIV infections, according to a presentation at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

Read more:

IAS 2015: First Brazilian Data Reinforce Evidence that PrEP is Mostly Used by Those at Greatest Risk

The first data from a Brazilian open-label demonstration project of HIV pre-exposure prophylaxis (PrEP) show, in common with several other studies presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver, that the higher a person’s risk of HIV infection, the more likely they are to seek and use PrEP.

alt

Read more:

IAS 2015: A Community Perspective on HIV Prevention Science [VIDEO]

Dazon Dixon Diallo from SisterLove, Inc. in Atlanta and the U.S. Women and PrEP Working Group offered a community perspective at a press briefing on early antiretroviral therapy (ART), treatment as prevention, and pre-exposure prophylaxis (PrEP) research at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver.

alt

Read more: